

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 January 2025 (16.01.2025)



(10) International Publication Number
WO 2025/015318 A2

(51) International Patent Classification:
C12N 5/07 (2010.01) C12N 5/0783 (2010.01)
C07K 14/54 (2006.01)

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(21) International Application Number:
PCT/US2024/037938

(22) International Filing Date:
12 July 2024 (12.07.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/513,550 13 July 2023 (13.07.2023) US
63/622,008 17 January 2024 (17.01.2024) US
63/562,210 06 March 2024 (06.03.2024) US
63/649,302 17 May 2024 (17.05.2024) US

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- without international search report and to be republished
upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))

(71) Applicant: **IOVANCE BIOTHERAPEUTICS, INC.**
[US/US]; 825 Industrial Road, Suite 400, San Carlos, CA
94070 (US).

(72) Inventors: **ZHANG, Yongliang**; 1436 Deerbourn Dr.,
Wesley Chapel, FL 33543 (US). **INNAMARATO,
Pasquale, Patrick, IV**; 1044 Anchor Bend Drive, Ruskin,
FL 33570 (US). **GILBERT, Nathan**; 518 Golden Rain-
tree Place, Brandon, FL 33510 (US). **YIN, Hequn**; 15471
Martinmeadow Dr., Lithia, FL 33547 (US). **VOGT, Fred-
erick G.**; 2120 Hemlock Road, West Norriton, PA 19401
(US). **HALL, Sean**; 1520 N. Pierce St., Unit 8, Tampa,
FL 33602 (US). **ERICKSON, Tim**; 1321 Sands Ter W,
Clearwater, FL 33764 (US). **PULIDO, Alvaro, De Mingo**;
19204 Hempstone Avenue, Poolesville, MD 20837 (US).

(74) Agent: **MACDOUGALL, Christina A.** et al.; Morgan,
Lewis & Bockius LLP, One Market, Spear Street Tower,
San Francisco, CA 94105 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: CYTOKINE ENCODING LENTIVIRAL VECTORS AND USES THEREOF FOR MAKING TUMOR INFILTRATING
LYMPHOCYTES

(57) Abstract: Provided herein are cytokine-encoding nucleic acid molecules, such as recombinant expression vectors, and uses thereof
to make modified tumor infiltrating lymphocytes (TILs), wherein the modified TILs include one or more immunomodulatory agents
(e.g. cytokines) associated with their cell surface. The immunomodulatory agents associated with the TILs provide a localized im-
munostimulatory effect that can advantageously enhance TIL survival, proliferation and/or anti-tumor activity in a patient recipient. As
such, the compositions and methods disclosed herein provide effective cancer therapies.



WO 2025/015318 A2